Image

Prediction of UA/SOD Ratio as a Biomarker of Oxidative Stress in Atrial Fibrillation

Prediction of UA/SOD Ratio as a Biomarker of Oxidative Stress in Atrial Fibrillation

Recruiting
18-90 years
All
Phase N/A

Powered by AI

Overview

To clarify the predictive effects of uric acid and superoxide dismutase as biomarkers of oxidative stress on atrial fibrillation, and to provide greater value for the diagnosis and prediction of atrial fibrillation. It provides a new idea for the prevention and treatment of atrial fibrillation.

Description

In recent years, a growing number of reports have shown the importance of oxidative stress in the pathophysiological mechanism of AF. During oxidative stress, there is an imbalance between the production of pro-oxidant reactive species and the antioxidant defenses of the cell, and excessive oxidation leads to oxidative damage and cell death. Redox processes can lead to atrial fibrosis and cardiac remodeling , suggesting that strategies to address myocardial oxidative stress may constitute a reasonable approach for the treatment of AF. However, few studies have reported the relationship between comprehensive oxidative stress-related biomarkers and AF. The purpose of this study was to illuminate the relationship of several blood markers of oxidative stress with AF and to provide new clues for the prevention and treatment of AF.

Eligibility

Inclusion Criteria: This retrospective study enrolled all hospitalized patients from

        January 2018 to December 2020 at the Department of Cardiology in The First Affiliated
        Hospital of Shandong First Medical University. The diagnosis of AF was based on 12-lead
        electrocardiography (ECG) or 24-hour Holter monitoring, and classification was based on the
        published 2020 ESC guidelines for the diagnosis and management of AF.
        Exclusion Criteria:
          1. acute heart failure and acute myocardial infarction;
          2. severe liver or kidney dysfunction (with aspartate aminotransferase or alanine
             aminotransferase levels three times higher than normal and estimated glomerular
             filtration rate <30 ml/ (min*1.73 m2));
          3. malignant tumors;
          4. missing data of laboratory indicators at baseline.

Study details
    Atrial Fibrillation
    Hyperuricemia

NCT06119802

Yinglong Hou

27 January 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.